Anti-Lung-Cancer Activity and Liposome-Based Delivery Systems ofβ-Elemene

Author:

Chen Meiwan1,Zhang Jinming1,Yu Siqin2,Wang Shengpeng1,Zhang Zaijun13,Chen Jianqiang4,Xiao Jian4,Wang Yitao1

Affiliation:

1. State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau 999078, China

2. Beijing DDS-Venturepharm .T. Corp, Beijing 100097, China

3. Institute of New Drug Research, Guangdong Province Key Laboratory of Pharmacodynamic, Constituents of Traditional Chinese Medicine & New Drug Research, College of Pharmacy, Jinan University, Guangdong 510632, China

4. School of Pharmacy, Cixi Hospital, Wenzhou Medical College, Wenzhou 325035, China

Abstract

In the past decade,β-elemene played an important role in enhancing the effects of many anticancer drugs and was widely used in the treatment of different kinds of malignancies and in reducing the side effects of chemotherapy. Further study showed that it is also a promising anti-lung cancer drug. However, the clinical application ofβ-elemene was limited by its hydrophobic property, poor stability, and low bioavailability. With the development of new excipients and novel technologies, plenty of novel formulations ofβ-elemene have improved dramatically, which provide a positive perspective in terms of clinical application forβ-elemene. Liposome as a drug delivery system shows great advantages over traditional formulations forβ-elemene. In this paper, we summarize the advanced progress being made in anti-lung cancer activity and the new liposomes delivery systems ofβ-elemene. This advancement is expected to improve the level of pharmacy research and provide a stronger scientific foundation for further study onβ-elemene.

Funder

National Natural Science Foundation of China

Publisher

Hindawi Limited

Subject

Complementary and alternative medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3